|
|
|
||||||||
|
NIMH Home
|
Lithium has long been used as a first-line treatment for manic-depressive disorder. Approved for the treatment of acute mania in 1970 by the U.S. Food and Drug Ad-ministration (FDA), lithium has been an effective mood-stabilizing drug for many people with manic-depressive disorder. Anticonvulsant medications, particularly valproate and carbamazepine, have been used as alternatives to lithium in many cases. Valproate was FDA approved for the treatment of acute mania in 1995. Newer anticonvulsant medications, including lamotrigine and gabapentin, are being studied to determine their efficacy as mood stabilizers in manic-depressive disorder. Some research suggests that different combinations of lithium and anticonvulsants may be helpful. During a depressive episode, people with manic-depressive disorder commonly require treatment with antidepressant medication. The relative efficacy of various antidepressant medications in this disorder has not yet been determined by adequate scientific study. Typically, lithium or anticonvulsant mood stabilizers are given along with an antidepressant to protect against a switch into mania or rapid cycling, which can be provoked in some people with manic-depressive disorder by antidepressant medications. In some cases, the newer, atypical anti-psychotic drugs such as clozapine or olanzapine may help relieve severe or refractory symptoms of manic-depressive disorder and prevent recurrences of mania. Further research is necessary, however, to establish the safety and efficacy of atypical antipsychotics as long-term treatments for manic-depressive disorder. Recent Research Findings More than two-thirds of people with manic-depressive disorder have at least one close relative with the illness or with unipolar major depression, indicating that the disease has a heritable component. Studies seeking to identify the genetic basis of manic-depressive disorder indicate that susceptibility stems from multiple genes. Despite tremendous research efforts, however, the specific genes involved have not yet been conclusively identified. Scientists are continuing their search for these genes using advanced genetic analytic methods and large samples of families affected by the illness. The researchers are hopeful that identification of susceptibility genes for manic-depressive disorder, and the brain proteins they code for, will make it possible to develop better treatments and preventive interventions targeted at the underlying illness process. Genetics researchers believe that a person's risk for developing manic-depressive disorder most likely increases with each susceptibility gene carried, and that inheriting just one of the genes is probably not sufficient for the disorder to appear. The particular mix of genes may determine various features of the illness, such as age of onset, type of symptoms, severity, and course. In addition, environmental factors are known to play an important role in determining whether and how the genes are expressed. New Clinical Trial The National Institute of Mental Health has initiated a large-scale study to determine the most effective treatment strategies for people with manic-depressive disorder. This multi-center study began in 1999. The study will follow patients and document their treatment outcome for 5 years. Source: National Institute of Mental Health awareness |
symptoms |
causes |
children | treatment | getting help HealthyPlace.com Bipolar Center Links home ~ site map |
|
|||||||
|
HealthyPlace.com Homepage © 2000-2008 HealthyPlace.com, Inc. All
rights reserved. |
|||||||||